Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.53 |
| ▸ | PKM | P14618 | 3/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | RGS12 | O14924 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21689933 | 1.00 | SLC7A5 (0.53) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL1769034 | 1.00 | SLC7A5 (0.53) | SLC7A5PKMPTGS1ALPIXIAP | |
| Hydrochloric Acid SCHEMBL20502478 | 0.98 | SLC7A5 (0.52) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL5285402 | 0.80 | ARG1 (0.44) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL31754299 | 0.79 | SLC7A5 (0.45) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL5285445 | 0.78 | SLC7A5 (0.46) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL22409316 | 0.77 | PTPRA (0.67) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL126509 | 0.77 | PTPRA (0.67) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL126508 | 0.77 | PTPRA (0.67) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL29039963 | 0.77 | NLRP3 (0.41) | ALDH1A1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6084065-A | FOR AGRICULTURAL USE | ISAGRO SPA (IT) | 2000-07-04 | — | — | US | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4558513-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024020159-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | WO | disclosed |
| US-11753446-B2 | Beta-hairpin peptidomimetics | POLYPHOR AG (CH) | 2023-09-12 | — | — | US | disclosed |
| CN-116496255-A | NLRP3 inhibitors | 杭州邦顺制药有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-11629171-B2 | Beta-hairpin peptidomimetics | SPEXIS AG (CH) | 2023-04-18 | — | — | US | disclosed |
| CN-115093463-A | Beta-hairpin peptidomimetics | 波利弗尔股份公司 | 2022-09-23 | — | — | CN | disclosed |
| US-11345669-B2 | Urea derivatives and methods of use thereof | NodThera Limited (GB) | 2022-05-31 | — | — | US | disclosed |
| EP-3201219-B1 | BETA-HAIRPIN PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2021-11-17 | — | — | EP | disclosed |
| EP-1196436-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001040262-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |
| US-6084065-A | FOR AGRICULTURAL USE | ISAGRO SPA (IT) | 2000-07-04 | — | — | US | disclosed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0787010-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
| EP-0652229-A2 | Oligopeptides with fungicidal activity | ISAGRO S.p.A. (IT) | 1995-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11629171-B2 | Beta-hairpin peptidomimetics | POLL, POLQ, HBZ | SLC7A5 1303/4885PKM 262/4885PTGS1 4119/4885 |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | SLC7A5 308/4885PKM 4530/4885PTGS1 3843/4885 |
| US-11345669-B2 | Urea derivatives and methods of use thereof | IL1B, IL1A, NOD1 | SLC7A5 4115/4885PKM 2439/4885PTGS1 208/4885 |
| US-11753446-B2 | Beta-hairpin peptidomimetics | POLL, BACE1, C1S | SLC7A5 3020/4885PKM 335/4885PTGS1 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.